![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.25 | 15.50 | 17.00 | 16.25 | 16.25 | 16.25 | 16,700 | 08:00:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.72 | 14.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/9/2017 13:33 | Interesting question but IF it was to happen, I would expect SBTX to double quicker on the right news, as its coming from a low market cap base. Only a bit of fun speculation though. | ![]() luminoso | |
07/9/2017 12:15 | shrewdmole,looking on the optimistic front, what will double first opti to 150p or sbtx to 26p ?, but that is a bit simplistic. | ![]() fathenry | |
07/9/2017 11:07 | Is anyone else wishing SACCO were listed? Apart from SBTX, that is where I would be looking to invest. SOH language in today's RNS is interesting. Stephen O'Hara, CEO of OptiBiotix, commented: "This invitation shows that OptiBiotix is being increasingly regarded as a KEY PLAYER in microbiome science and industrial biotechnology. The interest in our OptiScreen® and OptiBiotic® platforms suggests that the INDUSTRY BELIEVES we are developing commercially-attract | elrico | |
07/9/2017 10:01 | SBTX is a perfect play on Market Mechanics and growth story combined. No fear of placing, minuscule free float, and the seller (SpreadEx) close to exit. Added to that we have news due and the confidence in the technology through its association with OPTI | ![]() trotterstrading | |
07/9/2017 09:42 | Henry I don't think you will see long termers cashing in but it's possible a few traders that bought Opti in the 50's may take a bit off the table. Doesn't matter as the MM have been bidding strong last few days and it could be for ii interest. All guesswork tbh. S | ![]() shrewdmole | |
07/9/2017 09:17 | do you think some may be transferring their holding here to sbtx, for a possible higher return | ![]() fathenry | |
07/9/2017 09:16 | As Venture Life Group (LSE:VLG) is shown in the header graphic I will mention them here. I don't know if the tie up with OPTI is still live? last time I chcked with SOH they were still planning something. Nevertheless VLG on its own is an interesting proposition with growung sales in multiple teritories. Its UltraDEX range seems to be in all supermarkets I visit. Up on positive trading update today - but still only £20m valuation. Good growth story imo. | ![]() someuwin | |
07/9/2017 08:57 | parob, me too. could be a perfect storm there as spreadex are cleared out and imminent news hits. surprised volume isn't a bit higher off the back of opti's coverage recently though. opti still looks to me like theres a big buyer in the background to me. anyone know what online limits are, usually a telling sign either way. sm | ![]() shrewdmole | |
07/9/2017 08:55 | Grabbed a few more SBTX this morning. Price continues to rise there and so does the value of our free shares! | ![]() parob | |
07/9/2017 07:57 | World domination awaits!! :) | ![]() judijudi | |
07/9/2017 07:28 | Awareness of OPTI and its revolutionary science just keeps growing. | ![]() parob | |
07/9/2017 07:27 | Stephen O'Hara, CEO of OptiBiotix, commented: "This invitation shows that OptiBiotix is being increasingly regarded as a key player in microbiome science and industrial biotechnology. The interest in our OptiScreen(R) and OptiBiotic(R) platforms suggests that the industry believes we are developing commercially-attract | ![]() someuwin | |
07/9/2017 07:22 | Another great piece of news this morning. OPTI being invited to present in Spain amounts to international recognition of how important our science and products are. | ![]() rafboy | |
07/9/2017 06:50 | Elrico Your last post is spot on. When they announced Sacco I did suggest that was the last piece of the jigsaw required for the big boys to sign. They would have needed assurances that the product could be manufactured and supplied in very large scale. I also think that's how soh got such a good deal with Sacco as he would have said look I have p and g etc queuing up for this but I need someone to manufacture! I'm sure he will have used that stick! Anyway it would suggest a more rapid news flow on more deals. Keep up the good work. S | ![]() shrewdmole | |
07/9/2017 06:35 | 7 September 2017 OptiBiotix Health plc OptiBiotix invited to present at Expoquimia in Barcelona OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces it has been invited to present its research and commercial developments at the 18th edition of Expoquimia-World Chemical Summit (‘Expoquimia Expoquimia is a multidisciplinary event held triennially in which the industry, professional associations, governments and academia come together to discuss future opportunities and challenges in industrial chemistry and biotechnology. In its previous edition, it had over 600 exhibitors and 38,000 visitors, making it one of the largest industrial chemistry events in Europe. The Company will present the presentation titled: ‘New approaches: microbiome modulation as therapeutic intervention’, which will provide an overview of the wide array of existing strategies to modulate the microbiome to support human health, with a special focus on OptiBiotix’s technology platforms for the development of novel prebiotics and probiotics. Stephen O’Hara, CEO of OptiBiotix, commented: “This invitation shows that OptiBiotix is being increasingly regarded as a key player in microbiome science and industrial biotechnology. The interest in our OptiScreen® and OptiBiotic® platforms suggests that the industry believes we are developing commercially-attract | neftanikoff | |
07/9/2017 06:27 | I honestly do not think us buying the 40, 50,000 shares make a difference when we get the big funds coming in, or even the little ones, they will make a difference and the share price should power ahead, 100p by Xmas will be good | ![]() tony773 | |
06/9/2017 22:12 | ferdinand, i hadnt thought about the 4 way split valuation, it does demonstrate how cheap opti is. Eye opener for me. | incanus | |
06/9/2017 22:09 | I've said it many times before, the secret to OPTI's success will be SoH. Quite frankly the guy is a genius, the brightest and most business savvy CEO I've ever met, and I've met plenty in 20 years plus investing. Take a moment to stop and think what he has created, Slimbiome, LP LDL, sweetbitox, the SBTX IPO and more. It's simple, there is no one I trust more with my money | ![]() trotterstrading | |
06/9/2017 22:07 | Makes me think there's a good chance Tata could be the first partner for SweetBiotix. | ![]() parob | |
06/9/2017 21:47 | Tata are super-keen on the microbiome. An article from 2016:Tata Group tying up with Harvard and Yale for research; sets aside $25 millionhTTp://econom | ![]() parob | |
06/9/2017 21:26 | So hopefully this side of xmas an RNS will drop confirming the mighty TATA are launching a range of Slimbiome products in ASIA :o) | ![]() onedayrodders | |
06/9/2017 21:10 | people don't also realise that OPTI would get a lot more than the current valuation for selling their LDL strain. Not that they would. | ![]() jambam | |
06/9/2017 20:57 | I think this is what outside observers are missing with OPTI! They see a £60 million valuation and try to justify it based on current revenues! However, OPTI really is four companies in one and not just any old companies! Weight loss, cholesterol/ bp reduction, healthy sugars and skincare.They each have access to billion pound markets and are at the forefront of cutting edge science globally!Take our current market value and divide it by four you get an average £15 million valuation for each area. To me that is crazily cheap for the sheer potential each division has! | ![]() f3rdinand | |
06/9/2017 19:51 | From the results:OPTIBIOTICS® | ![]() riskybusiness1 | |
06/9/2017 18:07 | An afterthought...we now know SACCO held up the signature for four weeks post Vitafoods because the owner was on his jollies, which means August 22nd was official announcement. SACCO have been instrumental in the pace LP-LDL related deals have been concluded, TATA appears to be a prime example of this. I don't think it's a coincidence TATA was announced yesterday within weeks of SACCO concluding the global signature with OPTI. My guess is we will now start to see a multiple of national deals coming through and at any time we could have TATA/SlimBiome announcement. I would imagine we are getting very close to the inflection point, which may be assisted by the Las Vegas exhibition with SACCO, who already have a number of clients lined up wanting to use OPTI's LP-LDL. In terms of share price, I see very little negative and it we get revenue figures we could then see a big spike up, but until then, small incremental rises is good from here. Thank you all for you encouragement, PM's and emails, they are appreciated and makes the work more rewarding. | elrico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions